IRIS
PATRIGNANI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.370
EU - Europa 10.041
AS - Asia 9.712
SA - Sud America 1.170
AF - Africa 148
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 15
Totale 35.481
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.124
SG - Singapore 3.595
CN - Cina 3.014
UA - Ucraina 1.826
IE - Irlanda 1.433
GB - Regno Unito 1.315
TR - Turchia 1.253
RU - Federazione Russa 1.229
IT - Italia 1.063
BR - Brasile 971
SE - Svezia 906
VN - Vietnam 827
FR - Francia 824
DE - Germania 634
FI - Finlandia 378
IN - India 315
PL - Polonia 157
BD - Bangladesh 148
HK - Hong Kong 130
CA - Canada 119
AR - Argentina 86
MX - Messico 82
ES - Italia 59
ZA - Sudafrica 59
KR - Corea 56
JP - Giappone 54
IQ - Iraq 53
CZ - Repubblica Ceca 47
BE - Belgio 46
SA - Arabia Saudita 41
NL - Olanda 37
ID - Indonesia 31
EC - Ecuador 27
PK - Pakistan 25
CO - Colombia 24
UZ - Uzbekistan 22
AT - Austria 21
EU - Europa 21
IL - Israele 19
MA - Marocco 19
LT - Lituania 18
IR - Iran 16
AE - Emirati Arabi Uniti 15
PH - Filippine 15
VE - Venezuela 15
DZ - Algeria 14
PY - Paraguay 14
EG - Egitto 13
AU - Australia 12
CL - Cile 12
KE - Kenya 12
JM - Giamaica 11
MY - Malesia 11
JO - Giordania 10
PE - Perù 10
TN - Tunisia 10
OM - Oman 9
AZ - Azerbaigian 8
RO - Romania 7
BY - Bielorussia 6
GR - Grecia 6
HN - Honduras 6
KZ - Kazakistan 6
PS - Palestinian Territory 6
UY - Uruguay 6
BB - Barbados 5
CR - Costa Rica 5
LY - Libia 5
NP - Nepal 5
AL - Albania 4
AM - Armenia 4
BO - Bolivia 4
ET - Etiopia 4
LB - Libano 4
SN - Senegal 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
BA - Bosnia-Erzegovina 3
CG - Congo 3
CH - Svizzera 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
KW - Kuwait 3
PA - Panama 3
PT - Portogallo 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BH - Bahrain 2
BN - Brunei Darussalam 2
DM - Dominica 2
GA - Gabon 2
HR - Croazia 2
HU - Ungheria 2
LK - Sri Lanka 2
MN - Mongolia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
Totale 35.465
Salva come PNG Salva come JPEG
Città #
Singapore 2.453
Jacksonville 1.967
San Jose 1.855
Chandler 1.728
Dublin 1.423
Southend 1.002
Ashburn 783
Dallas 706
Princeton 705
Izmir 638
Beijing 610
Dearborn 568
Nanjing 494
Los Angeles 334
Cambridge 324
Council Bluffs 314
Wilmington 311
Ho Chi Minh City 281
Tongling 270
Santa Clara 202
Hanoi 201
Nanchang 200
The Dalles 186
Altamura 171
Buffalo 170
Boardman 160
New York 146
Chieti 144
Moscow 139
Shenyang 132
Woodbridge 120
Hong Kong 118
Ann Arbor 114
Hebei 93
Kraków 93
Munich 92
São Paulo 92
Tianjin 84
Grevenbroich 83
Jiaxing 75
Kunming 72
Changsha 68
Redondo Beach 61
Orem 58
Hangzhou 55
Warsaw 55
Hefei 52
Norwalk 52
Seoul 52
Rome 47
Jinan 46
Brooklyn 44
Denver 44
Chicago 43
Houston 43
Pescara 42
Tokyo 42
Brussels 41
Montreal 41
Washington 41
Johannesburg 40
Orange 39
Helsinki 37
Toronto 37
Brno 36
Chennai 33
Atlanta 32
Phoenix 32
Kocaeli 31
Milan 31
Guangzhou 30
Boston 29
Da Nang 29
Rio de Janeiro 29
Ningbo 28
Seattle 28
Shanghai 28
St Louis 28
Lanzhou 27
Mexico City 27
Haiphong 26
London 26
Zhengzhou 26
Augusta 25
Poplar 25
Frankfurt am Main 24
Hải Dương 24
Nuremberg 24
San Francisco 24
San Mateo 24
Belo Horizonte 23
Mumbai 23
Riyadh 23
Stockholm 23
Manchester 22
Amsterdam 21
Auburn Hills 21
Ankara 19
Camerino 19
Tashkent 19
Totale 21.672
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 245
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 184
Antithrombotic Agents and Cancer 182
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 172
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 167
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 164
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 157
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 156
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. 155
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 155
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 155
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 152
LA CASCATA DELL'ACIDO ARACHIDONICO 150
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 150
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 149
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 149
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 148
Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting 148
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 145
Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. 145
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 144
Dysregulation of gene expression in human fetal endothelial cells from gestational diabetes in response to TGF-β1 143
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 142
Effetto del propranololo e del suo metabolita attivo 4-OH propranololo sui prostanoidi COX-2 derivati e sull’emossigenasi-1 (OH-1) in cellule HUVEC. 140
Rare SNP rs12731181 in the miR-590-3p Target Site of the Prostaglandin F2α Receptor Gene Confers Risk for Essential Hypertension in the Han Chinese Population. 138
Thromboxane biosynthesis and pulmonary function in cystic fibrosis 137
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 137
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 136
A comparison of low-dose aspirin and dazoxiben as selective inhibitors of thromboxane A2 production in man. 135
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 135
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 135
Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk. 135
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 134
New insights into COX-2 biology and inhibition. 133
[ITALIAN CONSENSUS ON EULAR 2003 RECOMMENDATIONS FOR THE TREATMENT OF KNEE OSTEOARTHRITIS.] 133
Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology 133
A double-blind randomized study of the anti-platelet effects of low-dose ASA and placebo in patients after myocardial infarction 132
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 132
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 132
Therapeutic targeting of dysregulated cellular communication. 132
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 131
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 131
ALTERED RENAL AND PLATELET ARACHIDONIC ACID METABOLISM IN CIRRHOSIS. 130
Differential contribution of cycloooxygenase-isozymes to the generation of prostacyclin and prostaglandin E2 by endothelial cells in response to steady laminar shear stress 130
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 130
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 129
Clinical pharmacology of selective COX-2 inhibitors. 129
A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity. 129
Oxidative stress and platelet activation in essential hyperytension 128
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 127
Induction of prostacyclin by steady laminar shear stress suppresses Tumor Necrosis Factor-alfa biosyntesis via Heme Oxygenase-1 in human endothelial cells. 127
T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. 127
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 127
Determinants of platelet activation in human essential hypertension. 127
Platelet activation in patients with colorectal cancer. 126
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. 126
Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. 126
Aspirin and Cancer 126
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 124
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 124
RECOVERY OF THROMBOXANE BIOSYNTHESIS BY ASPIRIN-TREATED PLATELETS IN VITRO: A NOVEL MECHANISM OF ASPIRIN RESISTANCE. 123
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 123
Aspirin, platelet inhibition and cancer prevention. 123
A SELECTIVE THROMBOXANE-SYNTHASE INHIBITOR, ON PLATELET AND RENAL PROSTAGLANDIN ENDOPEROXIDE METABOLISM 122
AMPLIFICATION LOOPS: THROMBOXANE GENERATION. 122
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 122
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 122
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 122
Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients 121
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 121
Gut microbiota, host gene expression, and aging. 121
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 121
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 120
Risk management profile of etoricoxib: An example of personalized medicine 120
Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications 120
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 119
Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. 119
EFFECTS OF NIMESULIDE ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN MAN. 119
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 119
ANTIINFLAMMATORY COMPOUNDS L-745,337 AND NS-398 ARE SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 IN HUMAN BLOOD MONOCYTES 119
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 119
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 119
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 118
Clinical pharmacology of novel selective COX-2 inhibitors. 118
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 118
In vitro morphine metabolism by rat microglia. 118
Editorial: Eicosanoids in Cancer 118
Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies 118
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 117
Usefulness of enzimatic intermediate markers-example of cox-2 inhibition 117
Increased renal thromboxane production in Systemic Lupus Erythematosus. 117
ACTIVATED POLYMORPHONUCLEAR LEUKOCYTES INDUCE A PRO-INFLAMMATORY STATE OF THE ENDOTHELIUM 117
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 117
Mechanistic and pharmacological issues of aspirin as an anticancer agent 117
Induction of prostaglandin endoperoxide synthase 2 in monocytes of human whole blood is associated with cyclooxigenase-dependent isoprostane formation 116
Increased thromboxane production by monocyte prostaglandin endoperoxide synthase-2 in patients with acute myocardial infarction (pubbl. su Suppl. Circulation) 116
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 116
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 116
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 116
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 116
Totale 13.262
Salva come PNG Salva come JPEG
Categoria #
all - tutte 146.687
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 146.687
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021139 0 0 0 0 0 0 0 0 0 0 0 139
2021/20221.264 12 16 38 202 122 9 25 103 123 25 192 397
2022/20234.632 374 433 179 589 495 970 291 409 626 55 90 121
2023/20241.827 163 100 131 53 100 456 496 36 7 35 17 233
2024/20254.671 368 638 539 105 104 152 89 383 481 213 545 1.054
2025/202611.336 955 557 1.246 1.366 841 711 1.792 813 1.273 960 590 232
Totale 36.374